Choose from the two live presentation times below. Click the register button on the Microsoft Teams page to complete the form. A meeting link will be emailed to you upon registration.
Join us for a brief educational session highlighting upcoming enhancements to the Aegis behavioral health testing menu. Dr. Chris Burke will cover key clinical insights on these new analytes—lemborexant, viloxazine, benztropine, trihexyphenidyl and lumateperone—and their significance in behavioral health care.
Dr. Burke will delve into the clinical relevance of these additions, highlighting their pharmacologic profiles, therapeutic applications, and implications for patient care in behavioral health settings.
Learning Objectives
• Understand pharmacologic profiles
• Recognize indications for use
• Identify their role in therapy
• Interpret sample laboratory reports incorporating these new analytes
Potential causes of unexpected results in definitive testing
Learn more about circumstances that may impact testing protocols and result interpretation
Discusses the use of definitive testing for interacting substances and how the results can impact patient care